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Background.Theobjectiveofthispaperwastoexaminetheepidemiology,naturalhistory,andprognosticfactorsofcarcinosarcoma
of the kidney and renal pelvis (CSKP) using population-based registry. Patients and Methods. Forty-three patients with CSKP,
diagnosed between January 1973 and December 2007, were identiﬁed from the national Surveillance, Epidemiology, and End
Results (SEER) database and reviewed. Results. 79% of all patients with known SEER stage were classiﬁed as having regional or
distant stage; almost all the patients with known histology grade had poorly or undiﬀerentiated histology. The median cancer
speciﬁc survival was 6 months (95% CI 4–9). The 1-year cancer-speciﬁc survival rate for entire cohort was 30.2%. There were no
diﬀerences in terms of age at diagnosis, histological grade, tumor stage on presentation, and frequency of nephrectomy between
carcinosarcoma of kidney (CSK) or renal pelvis (CSP). In multivariate analysis, age at diagnosis, tumor stage, and year of diagnosis
werefoundtobesigniﬁcantpredictorsforcancer-speciﬁcsurvival.Conclusion.CSKPcommonlypresentedashigh-grade,advanced
stage disease, and was associated with a poor prognosis regardless of location.
1.Background
Carcinosarcoma (CS) is a highly aggressive tumor composed
ofmixedmalignantepithelialandmesenchymalcomponents
[1]. Carcinosarcoma of the kidney or renal pelvis (CSKP) is
a rare malignancy of the genitourinary system. To date, fewer
than 20 well-documented cases have been reported in the
medical literature [2–10]. Most of the reported cases were
carcinosarcoma of the renal pelvis (CSP) [2, 4–9]; only few
cases were from kidney (CSK) [3, 10].
The histogenesis of carcinosarcomas remains a matter
of controversy [3, 5, 8, 11]. Two main mechanisms were
suggested: the “collision” or “multiclonal” hypothesis posits
that the epithelial and mesenchymal components are distinct
coexisting populations with diﬀerent cells of origin [3].
The alternative “monoclonal” hypothesis suggests that carci-
nosarcomaarisesfromasinglemultipotentstemcellthatdif-
ferentiates along epithelial and mesenchymal pathways [11].
Due to the rareness of the disease, current literature on
carcinosarcoma of the genitourinary system predominantly
consists of a single case report and histopathological studies
[2–10], the demographic features and clinical behavior of
these tumors remain ill-deﬁned; in addition, the survival of
CSK and CSP was never directly compared.
In this study, a comprehensive analysis was performed to
examine the epidemiology, natural history, and prognostic
factors of patients with CSKP, and to determine if there was
any diﬀerence between CSK and CSP in term of clinical pres-
entation and outcome.
2. Methods
Data Source. The national Surveillance, Epidemiology, and
End Results (SEER) database currently consists of 18 state-
wide and regional tumor registries spread throughout the
US, covering approximately 26% of the population [12]. In
this study, we used the SEER data based on the November
2007 submission. Data for this study was obtained from
SEER Stat public-use data ﬁles, available from National
Cancer Institute.2 Advances in Urology
Table 1: Demographic and clinical characteristics of 43 patients with carcinosarcoma of kidney and renal pelvis (CSKP).
Characteristics Group N (%) Kidney (n = 23) Renal Pelvis (n = 20) P
Age mean (SD) 70 ±11 71 ± 13
Age <75 27 (62.8%) 14 13 0.78
≥75 16 (37.2%) 9 7
Gender Male 19 (44.2%) 11 8 0.16
Female 24 (55.8%) 12 12
Ethnicity White 38 (88.4%) 19 19 0.22
Nonwhite 5 (11.6%) 4 1
Married No 22 (51.2%) 13 9 0.45
Yes 21 (48.8%) 10 11
Grade
Low grade 1 (2.3%) 0 1
0.02 High grade 22 (51.2%) 8 14
Unknown 20 (46.5%) 15 5
SEER stage
Localized 7 (16.3%) 3 4
0.02 Regional 24 (55.8%) 9 15
Distant 10 (23.3%) 9 1
Unstaged 2 (4.7%) 2 0
Laterality Left 23 (53.5%) 15 8 0.10
Right 20 (46.5%) 8 12
Nephrectomy
Yes 32 (74.4%) 14 18
0.05 Unknown surgery 5 (11.6%) 5 0
No 6 (14%) 4 2
Adjuvant Radiation Yes 2 (4.7%) 2 0 0.28
No 41 (95.3%) 21 20
Year of diagnosis 1973–1988 7 (16.3%) 6 1 0.07
1989–2004 36 (83.7%) 17 19
High grade: poorly diﬀerentiated or undiﬀerentiated.
Study Population. The cases of carcinosarcoma were extract-
ed from SEER on the basis of anatomic site (kidney 64.9,
renal pelvis 65.9) and histologic type (ICD-Ocode 8980 and
8981). Patients over the age of 18 years, ﬁrst diagnosed
and/or treated between January 1973 and December 2007,
were enrolled in this study.
2.1. Statistical Analysis. Patients were divided into 2 groups
according to location (kidney versus renal pelvis). Student’s
t-test and the χ2 test were, respectively, used for comparison
of means and proportions between two groups. Survival
duration was measured by the Kaplan-Meier method and
compared by the log rank test [13]. Cases identiﬁed at the
t i m eo fa u t o p s yo rb yd e a t hc e r t i ﬁ c a t eo n l yw e r ee x c l u d e d
from the survival analyses. Multivariable Cox proportional
hazards model was used to identify independent predictors
of long-term cancer speciﬁc death [14]. All statistical cal-
culations were performed by SPSS 12.0 (Apache Software
Foundation 2000). Comparative diﬀerences were considered
statistically signiﬁcant when the P value was <0.05.
3. Results
3.1. Patient and Tumor Characteristics. Forty-three patients
with CSKP were identiﬁed in the SEER database during the
study period, with a median age of 72 years (range 40–97).
The majority of patients (88.4%) were white. Twenty-three
percent of patients in the study were classiﬁed with distant
stage disease. Except one patient, all the rest of patients
with known histology had high-grade disease (poorly or
undiﬀerentiated histology). Overall, 74.4% of study subjects
had radical nephrectomy, and 4.7% of patients had adjuvant
radiation therapy.
Details regarding demographics, tumor characteristics,
and treatment information are summarized in Table 1.
Survival Analysis. For survival analyses, one patient that was
diagnosed at the time of autopsy was excluded. A total of 42
patents were included in ﬁnal survival analysis. The median
duration of followup of the entire cohort was 5 months
(range 0–146); 40 of 42 (95.2%) patients died during the
follow-up period. The median cancer-speciﬁc survival was
6 months (95% CI 4–9; Figure 1(a)). The 1-year cancer
speciﬁc survival rate for entire cohort was 30.2%. There was
a signiﬁcant diﬀerence of cancer-speciﬁc survival between
patients with localized/regional disease and distant disease
(P = 0.02; Figure 1(b)).
ThemediansurvivalforCSKwas5months(95%CI1–9)
and for CSP was 6 months (95% CI 4–8; Table 2). There
werenosigniﬁcantdiﬀerencesincancer-speciﬁcsurvivalrate
betweenCSPandCSK(P = 0.42;Figure 1(c)).Inamultivar-
iate survival analyses by Cox proportional hazard modeling,Advances in Urology 3
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Figure1:(a)Cancer-speciﬁcsurvivalrateofpatientswithcarcinosarcomaofthekidneyandrenalpelvis(CSKP).(b)Cancer-speciﬁcsurvival
rate according to stage. (c) Cancer-speciﬁc survival rate according to tumor location.
only age at diagnosis, tumor stage and year of diagnosis
were identiﬁed as independent factors associated with cancer
specific survival (Table 3).
4. Discussion
Most patients in this study presented with high histological
grade and advanced-stage disease at the time of presentation:
79% of all patients with known SEER stage were classiﬁed as
having regional or distant stage; almost all the patients (22
out of 23) with known histology grade had poorly or undif-
ferentiated histology. The clinical and pathological charac-
teristics of our study subjects were consistent with previous
ﬁndings that CSKP is a very aggressive tumor [2–10]. These
ﬁndings underscore the importance of early detection and
diagnosis in this disease.
Since there is no clinical trial speciﬁcally designed for
CSKP, the optimal treatment strategy has not been estab-
lished. Nephrectomy, radiation therapy, or chemotherapy
has been used alone or in combination [3, 5]. Chen et al. re-
ported the longest survival period, which is two years [8].
There was no survival beneﬁt with the addition of post-
operative chemotherapy, radiation, or combination [2, 5].
Consistent with single institution studies, the survival of4 Advances in Urology
Table 2: Median, 1-, 3-year cancer speciﬁc survival of patients with carcinosarcoma of kidney and renal pelvis (CSKP) according to demo-
graphic and clinical characteristics.
Characteristics Median cancer speciﬁc survival months
(95% CI)
Survival (%) 6 months, 1 year, 3 year P value
All 6 (4–9) 48.4 30.2 19.6
SEER stage
Local/regional 7 (5–9) 86.6 79.4 22.4 0.02
Distant 4 (2–6) 16.7 16.7 0.00
Nephrectomy
No 3 (0–6) 40.0 20.0 20.0 0.77
Yes 7 (5–9) 50.9 31.3 18.8
Location
Kidney 5 (1–9) 48.3 36.8 18.4 0.42
Renal Pelvis 6 (4–8) 48.6 21.3 21.3
Table 3: Multivariate analyses of factors associated with mortality in patients with carcinosarcoma of kidney and renal pelvis (CSKP).
Characteristics Group HR (95% CI) P value
Age <75 1.00 (1.19–8.33) 0.02
≥75 3.16
Gender Female 1.00 (0.90–4.82) 0.085
Male 2.08
SEER stage Distant 1.00 (.096–0.74) 0.011
Localized/regional 0.27
Location Renal pelvic 1.00 (0.29–1.63) 0.40
Kidney 0.69
CDS No 1.00 (0.29–5.64) 0.75
Nephrectomy 1.28
Diagnosis year 1973–1984 1.00 (0.02–0.77) 0.025
1985–2004 0.13
HR: harzard ratio; SEER: Surveillance, Epidemiology, and End Results.
CDS: cancer directed surgery.
patients in our study cohort was extremely poor. We did,
however, observe a signiﬁcant improvement in the outcome
of patients with CSKP over time (Table 3). The improved
outcomes over time likely reﬂect the advance in surgical
techniques, and the increased adoption of multidisciplinary
care. Further study to understand the molecular mechanism
underlining the aggressive biological behavior of CSKP and
the development of new strategies and aggressive therapeutic
approaches for this tumor are urgently needed.
Strengths of this study include the populations-based
design, with cases from a broad spectrum of hospitals.
Population studies are of particular importance for analysis
o fr a r es u b t y p ec a n c e rs u c ha sC S K Pw h e r e ,t od a t e ,n o
singleinstitutionstudyhasenoughcasestomakemeaningful
analysis regarding important prognostic factors.
Our ﬁndings have several limitations. First, the patho-
logical diagnoses in SEER are based on local pathologists’
reports and there is no central review of pathology reports.
Unlike single-institution studies, the accuracy of staging and
pathologic diagnosis within a national registry may vary
widely across the institutions. Second, SEER data did not
allow us to examine receipt of chemotherapy and patients’
comorbidities, as well as performance status, all of which
may inﬂuence survival in cancer patients. The analysis
reported here attempted to overcome this data limitation
by measuring cancer-speciﬁc survival, rather than overall
survival. Finally, the sample size in our study may still not
be large enough to fully describe the factors that aﬀect
the incidence, treatment choice, and survival of this rare
malignancy.
5. Conclusions
In summary, CSKP is a highly malignant neoplasm, usually
presented in elder males with an advanced stage at pre-
sentation and was rapidly lethal. A better understanding of
the natural history of this disease and prognostic factors
as provided herein are necessary to allow physicians and
patients to accurately assess the risks and potential beneﬁts
of available therapy.Advances in Urology 5
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